Ana Paula Galli Sanchez, Tatiane Ester Aidar Fernandes
{"title":"Dupilumab对IL - 4和IL - 13的同时抑制作用","authors":"Ana Paula Galli Sanchez, Tatiane Ester Aidar Fernandes","doi":"10.15226/2378-1726/8/2/001138","DOIUrl":null,"url":null,"abstract":"Interleukins (IL) IL-4 and IL-13 are key players in diseases in which the Type 2 immune response is predominant, such as atopic dermatitis (AD), asthma, and chronic rhinosinusitis with nasal polyposis (CRSwNP), that are currently being treated with dupilumab. Dupilumab is a fully human IgG4 monoclonal antibody that targets the IL-4 receptor alpha chain (IL-4Rα), preventing both IL-4 and IL-13 mediated signaling. This mini-review summarizes the IL-4 receptor system as well as the mechanism of action of dupilumab. Keywords: IL-4; IL-13; dupilumab; Type 2 immunity Abbreviations AD: Atopic Dermatitis CRSwNP: Chronic Rhinosinusitis with Nasal Polyps DNA: Deoxyribonucleic Acid JAK: Janus Kinase IL: Interleukin IL-4R: Interleukin 4 Receptor IL-4Rα: Interleukin 4 Receptor alpha chain IL-13Rα1: Interleukin 13 Receptor alpha 1 chain IL-13Rα2:Interleukin 13 Receptor alpha 2 chain STAT: Signal Transducer and Activator of Transcription TGF-β: Transforming Growth Factor beta TNF: Tumor Necrosis Factor TYK2: Tyrosine Kinase 2 γc: Common gamma chain","PeriodicalId":15481,"journal":{"name":"Journal of Clinical Research in Dermatology","volume":"25 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Simultaneous Inhibition of IL‑4 and IL‑13 by Dupilumab\",\"authors\":\"Ana Paula Galli Sanchez, Tatiane Ester Aidar Fernandes\",\"doi\":\"10.15226/2378-1726/8/2/001138\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Interleukins (IL) IL-4 and IL-13 are key players in diseases in which the Type 2 immune response is predominant, such as atopic dermatitis (AD), asthma, and chronic rhinosinusitis with nasal polyposis (CRSwNP), that are currently being treated with dupilumab. Dupilumab is a fully human IgG4 monoclonal antibody that targets the IL-4 receptor alpha chain (IL-4Rα), preventing both IL-4 and IL-13 mediated signaling. This mini-review summarizes the IL-4 receptor system as well as the mechanism of action of dupilumab. Keywords: IL-4; IL-13; dupilumab; Type 2 immunity Abbreviations AD: Atopic Dermatitis CRSwNP: Chronic Rhinosinusitis with Nasal Polyps DNA: Deoxyribonucleic Acid JAK: Janus Kinase IL: Interleukin IL-4R: Interleukin 4 Receptor IL-4Rα: Interleukin 4 Receptor alpha chain IL-13Rα1: Interleukin 13 Receptor alpha 1 chain IL-13Rα2:Interleukin 13 Receptor alpha 2 chain STAT: Signal Transducer and Activator of Transcription TGF-β: Transforming Growth Factor beta TNF: Tumor Necrosis Factor TYK2: Tyrosine Kinase 2 γc: Common gamma chain\",\"PeriodicalId\":15481,\"journal\":{\"name\":\"Journal of Clinical Research in Dermatology\",\"volume\":\"25 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Research in Dermatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15226/2378-1726/8/2/001138\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Research in Dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15226/2378-1726/8/2/001138","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The Simultaneous Inhibition of IL‑4 and IL‑13 by Dupilumab
Interleukins (IL) IL-4 and IL-13 are key players in diseases in which the Type 2 immune response is predominant, such as atopic dermatitis (AD), asthma, and chronic rhinosinusitis with nasal polyposis (CRSwNP), that are currently being treated with dupilumab. Dupilumab is a fully human IgG4 monoclonal antibody that targets the IL-4 receptor alpha chain (IL-4Rα), preventing both IL-4 and IL-13 mediated signaling. This mini-review summarizes the IL-4 receptor system as well as the mechanism of action of dupilumab. Keywords: IL-4; IL-13; dupilumab; Type 2 immunity Abbreviations AD: Atopic Dermatitis CRSwNP: Chronic Rhinosinusitis with Nasal Polyps DNA: Deoxyribonucleic Acid JAK: Janus Kinase IL: Interleukin IL-4R: Interleukin 4 Receptor IL-4Rα: Interleukin 4 Receptor alpha chain IL-13Rα1: Interleukin 13 Receptor alpha 1 chain IL-13Rα2:Interleukin 13 Receptor alpha 2 chain STAT: Signal Transducer and Activator of Transcription TGF-β: Transforming Growth Factor beta TNF: Tumor Necrosis Factor TYK2: Tyrosine Kinase 2 γc: Common gamma chain
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
